MedChinaGo
China's 10 Approved CAR-T Products: The Complete 2026 List
November 10, 2026·Updated November 21, 2026|10 min read

China's 10 Approved CAR-T Products: The Complete 2026 List

Every NMPA-approved CAR-T, its target, its label and its list price

OncologyTreatment GuideCancer TreatmentImmunotherapyCost in ChinaMedical TourismWhy Choose China?

All ten NMPA-approved CAR-T products in China — target, indication, approval date and list price — plus how haematologists choose between them.

Ten products, three targets, one question

As of November 2026, China's drug regulator has approved ten CAR-T cell therapies — more than the seven approved by the US FDA. Six target CD19, three target BCMA, and one targets CLDN18.2. Most were developed inside China and are not sold anywhere else in the world.

For a patient or a referring oncologist, the useful question is no longer "does China have CAR-T?" It is: which of the ten matches this diagnosis, at which line of therapy, and at what price?

This guide lists all ten with their target, approved indication, approval date and published price — then explains how Chinese hematologists actually choose between them, and where the gaps are.

Cartoon illustration of ten labeled medicine vials standing on a clean shelf, grouped in three color-coded clusters — blue, green and orange — each cluster with a small target icon above it. Bright flat vector cartoon style, warm clinic background, no text

The complete list

Chinese brand names are included because several products have no English brand name outside China. Prices are manufacturer list prices per infusion, from published Chinese industry reporting.

Product (brand) Generic name Target Approved for Approved List price
奕凯达 axicabtagene ciloleucel (axi-cel) CD19 Relapsed/refractory large B-cell lymphoma, 2nd line or later Jun 2021 ¥1.20M
倍诺达 relmacabtagene autoleucel (relma-cel) CD19 Large B-cell lymphoma; follicular lymphoma; mantle cell lymphoma Sep 2021 ¥1.299M
源瑞达 inaticabtagene autoleucel (inati-cel) CD19 Adult B-cell acute lymphoblastic leukemia; large B-cell lymphoma Nov 2023 / Nov 2025 ¥0.999M
福可苏 equecabtagene autoleucel (eque-cel) BCMA Multiple myeloma after ≥3 prior lines Jun 2023 ¥1.166M
赛恺泽 zevorcabtagene autoleucel (zevor-cel) BCMA Multiple myeloma after ≥3 prior lines 2024 ¥1.15M
恒凯莱 ranicabtagene autoleucel (rani-cel, HICARA) CD19 Relapsed/refractory large B-cell lymphoma Jul 2025 ¥0.899M
普利得凯 puzolcabtagene autoleucel (puzo-cel) CD19 B-ALL in patients aged 3–21 Nov 2025 ¥0.998M
西达基奥仑赛 ciltacabtagene autoleucel (cilta-cel) BCMA Relapsed/refractory multiple myeloma Aug 2024 Not published in China
恺力美 satricabtagene autoleucel (satri-cel) CLDN18.2 CLDN18.2-positive, HER2-negative advanced gastric / GEJ cancer Jun 2026 ¥0.99M
赛泊华 IM19 (泊基奥仑赛) CD19 Relapsed/refractory large B-cell lymphoma, 2nd line or later Nov 2026 Not yet published

Two things stand out from the table. First, the price band is remarkably tight: ¥899,000 to ¥1,299,000 — roughly $135,000 to $195,000 at ¥6.67 to the dollar on 21 November 2026 — regardless of whether the product is a first-generation CD19 therapy or the newest arrival. Second, two of the ten have no published price at all, which matters for planning.

Why the target decides everything

CAR-T is not one drug. It is a platform that gets pointed at one marker on one cell type. The target determines which cancer it can touch, and the choice is not a matter of preference — it is a matter of biology.

CD19 sits on the surface of B cells. When B cells turn malignant, the same marker stays on the surface, which makes CD19 the oldest and most crowded target in CAR-T: lymphoma and acute lymphoblastic leukemia.

BCMA sits on plasma cells — the antibody-producing cells that multiple myeloma arises from. It is the myeloma target.

CLDN18.2 is different. It is a protein on the surface of gastric and gastroesophageal junction cancer cells, and in June 2026 it became the target of the first CAR-T approved anywhere in the world for a solid tumor. Blood cancers float; solid tumors build walls of stroma and hostile microenvironment around themselves, which is why solid-tumor CAR-T took nine years longer.

Cartoon illustration of three stylized cell surfaces side by side, each with a different glowing surface marker and a small label icon above it, with a matching cancer cell type drawn beside each. Bright flat vector cartoon style, clean educational composition, no text

The six CD19 products

Six approved products aim at CD19, and they are not interchangeable — each carries a different slice of the lymphoma and leukemia map.

relma-cel (倍诺达) is the only product with approved indications in all three main non-Hodgkin lymphoma types: large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. In its registrational RELIANCE study, objective response was 82% in patients at third line or beyond, with a 2-year overall survival around 69%. For follicular or mantle cell patients, this is currently the only approved commercial option in China.

inati-cel (源瑞达) is the only CD19 product approved for both adult B-ALL and large B-cell lymphoma. In the B-ALL registrational study, three-month objective response was 85.4%, MRD negativity reached 100%, and 2-year overall survival was 55.2%. Long-term follow-up in lymphoma showed a 5-year overall survival of 37.5%.

axi-cel (奕凯达) was China's first approved CAR-T, in June 2021, and remains the local reference product for large B-cell lymphoma. It is the only product on this list that also has a US FDA approval under the same brand family — useful context when your home oncologist is familiar with the Western label.

IM19 (赛泊华) is the newest, approved on 5 November 2026 for relapsed or refractory large B-cell lymphoma after two or more lines. Its confirmatory study enrolled 101 infused patients and reported a three-month objective response of 57%, best objective response 71%, best complete response 41%, median progression-free survival 5.98 months and one-year overall survival 63.7%. The safety profile is the selling point: grade ≥3 cytokine release syndrome in 1.0%, and no grade ≥3 neurotoxicity. In the two hardest groups — patients over 65 and patients who relapsed after a stem cell transplant — best objective response reached 80.8% and 90% respectively.

rani-cel (恒凯莱, HR001) is a domestic CD19 product approved in July 2025 for large B-cell lymphoma, built on a CD28 costimulatory domain with a manufacturing process that the developer claims cuts raw-material cost to about a third of comparable products.

puzo-cel (普利得凯) is China's first CAR-T approved for children and adolescents — ages 3 to 21 with relapsed or refractory B-ALL. In its pivotal study, best objective response was 97.6%, best complete response 84.5%, and MRD negativity 98.8%. Grade ≥3 cytokine release syndrome occurred in 27%, notably lower than the historical pediatric benchmark.

The three BCMA products

All three are for multiple myeloma after at least three prior lines, and they compete on depth of response rather than on target.

eque-cel (福可苏) reported an objective response of 96% and a complete response or better of 74.3% in its pivotal study, with grade ≥3 cytokine release syndrome in about 1% — an unusually clean safety profile for the class.

zevor-cel (赛恺泽) is the second domestic BCMA product, approved in 2024, and priced slightly below eque-cel.

cilta-cel (西达基奥仑赛) is the Chinese-developed, globally licensed BCMA product best known internationally as Carvykti. It has been approved in China since August 2024 but has no published domestic list price.

All three are labelled for later lines. What to do at first relapse, where a BCMA bispecific now competes with them, is a separate question — CAR-T or bispecific first in myeloma covers the sequencing.

The one solid-tumor product

satri-cel (恺力美) was approved on 22 June 2026 for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. It is the first CAR-T approved for a solid tumor anywhere, and it comes with a different access model: the manufacturer published a list of 64 certified treatment centres, because CLDN18.2 testing and gastric-cancer infusion protocols are not available at every hematology unit.

For gastric cancer patients in countries where this indication has no approved cell therapy at all, it is the single most consequential approval on this list.

What the price band actually includes

The ¥899,000–¥1,299,000 figure is the product price — the manufactured cell dose. It is not the bill.

Realistic total cost of care in China adds ¥150,000–¥400,000 for the parts around the product: leukapheresis, bridging or lymphodepletion chemotherapy, inpatient monitoring on a dedicated CAR-T ward, ICU contingency, imaging, and follow-up through Day 90. That puts a typical all-in course at roughly $157,000–$255,000.

Two honest notes on payment:

  • Chinese patients enrolled in city-level supplementary commercial insurance schemes have seen out-of-pocket costs fall sharply — reported cases show reimbursement of several hundred thousand yuan. International self-pay patients do not qualify for these schemes, so the list price is the price.
  • The two products without a published price are not necessarily more expensive. Unpublished pricing usually means the manufacturer is negotiating provincial procurement or commercial insurance listing, and the treating hospital will quote directly.

Compare that with the United States, where FDA-approved CAR-T products list at $373,000–$475,000 for the drug alone, and the full pathway — hospitalisation, ICU, supportive care — routinely runs past $500,000 and can exceed $1,000,000.

Which product fits which diagnosis

Diagnosis Approved option in China
Large B-cell lymphoma, 2nd line or later axi-cel, relma-cel, inati-cel, rani-cel, IM19
Follicular lymphoma relma-cel (only approved option)
Mantle cell lymphoma relma-cel (only approved option)
Adult B-ALL inati-cel
B-ALL, ages 3–21 puzo-cel
Multiple myeloma, ≥3 prior lines eque-cel, zevor-cel, cilta-cel
Gastric / GEJ cancer, CLDN18.2+, HER2− satri-cel

Cartoon illustration of a clean decision map: a central patient icon with branching arrows leading to four labelled groups of disease icons, each group connected to a small cluster of medicine vial icons. Bright flat vector cartoon style, simple and readable, no text

What is not approved in China

Three of the most familiar Western CAR-T brands — Kymriah (tisagenlecleucel), Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel) — have never been approved in mainland China.

This matters practically. If your oncologist at home has planned one of those specific products, the Chinese team will not substitute a "Chinese version" of the same brand. It will map the case onto the same target and indication and choose from the ten above. For a CD19 lymphoma patient that is a straightforward equivalence question. For a patient whose plan depended on a specific product's trial data, it is a conversation worth having before you book flights.

Beyond the ten: the trial route

The approved list covers CD19, BCMA and CLDN18.2. It does not cover T-cell malignancies, hepatocellular carcinoma, pancreatic cancer, or most solid tumors — and that is where China's trial landscape becomes relevant.

China runs the largest portfolio of registered CAR-T trials in the world, with active programs against CD7 and CD5 for T-cell leukemia and lymphoma, GPC3 for liver cancer, CLDN18.2 for pancreatic cancer, and dual-target constructs such as BCMA × CD19 for myeloma. For a patient who has exhausted approved options at home and does not fit any of the ten products, a trial is often the only realistic route — and it is a genuinely different conversation from commercial treatment, with different consent, different costs and different uncertainty.

How the choice is actually made

In practice, a Chinese CAR-T team works through five filters, in this order:

  1. Target expression. CD19 by flow cytometry or immunohistochemistry, BCMA by pathology, CLDN18.2 by IHC with a documented positivity threshold. No target, no product.
  2. Indication match. The approved label — not the mechanism — decides. A CD19 product approved for lymphoma is not automatically available for B-ALL.
  3. Line of therapy. Most of these labels are for second line or later; a few are third line or later. Earlier-line use usually means a trial.
  4. Centre certification. NMPA requires each product to be given only at hospitals certified for it. Certification lists range from a handful of centres to more than a hundred, which directly affects waiting time.
  5. Written, itemised quote. Product, apheresis, lymphodepletion, ward, ICU contingency, follow-up — item by item, in writing, before payment.

Which of these can be settled from the paperwork alone, and which needs you physically in a Chinese hospital, is set out in the patient journey guide.

The honest caveats

Volume of approvals is not the same as proven superiority. Ten approvals mean more choice and more competition on price; they do not mean any single product is better than the best Western product for your disease.

Several approvals are conditional. At least five of the ten carry an approval contingent on confirmatory data, which means the evidence package can still change. Ask which of your product's indications is conditional, and what happens to your access if the confirmatory data fall short.

List price is the ceiling, not the invoice. Discounts and procurement negotiations are confidential and vary by province and by centre. The number you are quoted may be lower than the published figure — and the number you are quoted for the full course will be higher than the product price.

One infusion is not one decision. CAR-T is a single infusion followed by weeks of monitoring, and roughly a third of lymphoma patients will eventually progress. Planning for what happens after infusion — including whether a transplant should follow — matters as much as choosing the product.

If the patient is a child, read our guide to CAR-T for children with relapsed B-ALL in China first — the paediatric indication, the trial data and the bridge to transplant work differently from the adult pathway.

Getting started with CAR-T in China

If you are trying to work out which of the ten products your diagnosis actually points to, the first step is a free record review: pathology report, target-expression results, imaging and a full treatment history. MedChinaGo's CAR-T program reviews records against the current NMPA label list and trial portfolio, and coordinates treatment at certified centres with dedicated CAR-T wards and senior oncology-trained interpreters from review through Day 90 follow-up. Learn more about CAR-T therapy in China, or read our comparison of CAR-T, transplant and chemotherapy if the decision between treatment types is still open.

Frequently Asked Questions

Author

M

MedChinaGo Medical Team

Medical Tourism Specialists

https://www.chinamedicaltrips.com/about

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for personal medical decisions.

Ready to Start Your Medical Journey?

Contact us today for a free consultation and personalized treatment plan

Free Consultation